Next Article in Journal
Low-Power Sonication Can Alter Extracellular Vesicle Size and Properties
Next Article in Special Issue
Evaluation of Effects of Ractopamine on Cardiovascular, Respiratory, and Locomotory Physiology in Animal Model Zebrafish Larvae
Previous Article in Journal
Diabetes Mellitus and Periodontitis Share Intracellular Disorders as the Main Meeting Point
Previous Article in Special Issue
Development of Tg(UAS:SEC-Hsa.ANXA5-YFP,myl7:RFP); Casper(roy−/−,nacre−/−) Transparent Transgenic In Vivo Zebrafish Model to Study the Cardiomyocyte Function
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 10
Issue 9
10.3390/cells10092412
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Mechanisms of Fibroblast Activation and Myocardial Fibrosis: Lessons Learned from FB-Specific Conditional Mouse Models

by
Prachi Umbarkar
1,*,
Suma Ejantkar
2,
Sultan Tousif
1 and
Hind Lal
1,*
1
Division of Cardiovascular Disease, The University of Alabama at Birmingham, Birmingham, AL 35294, USA
2
School of Health Professions, The University of Alabama at Birmingham, Birmingham, AL 35294, USA
*
Authors to whom correspondence should be addressed.
Cells 2021, 10(9), 2412; https://doi.org/10.3390/cells10092412
Submission received: 17 August 2021 / Revised: 9 September 2021 / Accepted: 10 September 2021 / Published: 14 September 2021
(This article belongs to the Collection Cardiovascular Disease: From Molecular and Cellular Mechanisms to Therapeutic Opportunities)
Browse Figures
Versions Notes

Abstract

:
Heart failure (HF) is a leading cause of morbidity and mortality across the world. Cardiac fibrosis is associated with HF progression. Fibrosis is characterized by the excessive accumulation of extracellular matrix components. This is a physiological response to tissue injury. However, uncontrolled fibrosis leads to adverse cardiac remodeling and contributes significantly to cardiac dysfunction. Fibroblasts (FBs) are the primary drivers of myocardial fibrosis. However, until recently, FBs were thought to play a secondary role in cardiac pathophysiology. This review article will present the evolving story of fibroblast biology and fibrosis in cardiac diseases, emphasizing their recent shift from a supporting to a leading role in our understanding of the pathogenesis of cardiac diseases. Indeed, this story only became possible because of the emergence of FB-specific mouse models. This study includes an update on the advancements in the generation of FB-specific mouse models. Regarding the underlying mechanisms of myocardial fibrosis, we will focus on the pathways that have been validated using FB-specific, in vivo mouse models. These pathways include the TGF-β/SMAD3, p38 MAPK, Wnt/β-Catenin, G-protein-coupled receptor kinase (GRK), and Hippo signaling. A better understanding of the mechanisms underlying fibroblast activation and fibrosis may provide a novel therapeutic target for the management of adverse fibrotic remodeling in the diseased heart.

Graphical Abstract

1. Introduction

Fibrosis is characterized by the excessive accumulation of extra cellular matrix (ECM) components. It is a physiological response to pathological stimuli that helps to confine injuries. However, the prolonged activation of this process results in adverse tissue remodeling, which can ultimately affect the structure and function of organs (adverse remodeling). Fibroblasts (FBs) are the major contributor to fibrosis. Previous studies report that the epicardium, endothelial cells, bone-marrow-derived cells, and perivascular cells could be the origins of activated FBs [1,2,3,4,5,6,7,8]. However, recent genetic lineage tracing experiments have confirmed that most activated FBs in the heart originate from tissue-resident FBs [9,10,11,12]. In a normal heart, FBs are quiescent/resting/non-activated. However, in the injured heart, FBs go through a continuum of transient intermediary states and contribute significantly to the cardiac remodeling process [13,14,15,16]. For instance, when myocardial infarction (MI) occurs, a range of stimuli activate resting FBs, giving rise to a new cell state known as activated FBs/myofibroblast. Activated FBs are pro-inflammatory, hyper-secretory, and hyper-migratory in nature. As the healing phase progresses towards scar formation, activated FBs acquire anti-inflammatory and pro-angiogenic phenotypes. They secrete cytokines, ECM components, and other necessary paracrine factors that are required for wound healing. After scar maturation, FBs regress to the quiescent stage or acquire a specialized phenotype (matrifibrocyte) and remain in the matured scar [14,16]. A better understanding of the mechanisms underlying fibroblast activation and fibrosis may provide a novel therapeutic target for managing adverse fibrotic remodeling in the diseased heart.

2. Studies of FB-Specific In Vivo Mouse Models

Recent advancements in the generation of FB-specific mouse models have evolved the field of fibroblast biology. Table 1 lists proteins/markers that have been targeted to create numerous mouse lines for FB-specific genetic manipulation and lineage tracing. The major limitation associated with these models is non-specificity, as many of these markers are expressed by cells other than FBs such as pericytes, vascular smooth muscle cells (VSMC), endothelial cells, immune cells, and cardiomyocytes or show transient expression in FBs. Several studies have employed fibroblast-specific protein 1 (FSp1)-Cre and Col1a2-Cre for fibroblast-specific gene targeting [6,17]. However, in recent years, a growing body of evidence has challenged the specificity of FSP1 and COL1A2 as fibroblast markers [18,19]. Kong et al. [18] reported that the majority of FSP1+ cells in the infarcted myocardium are identified as hematopoietic or endothelial cells; therefore, FSP1 is not a specific marker for FBs in the heart. Consistently, in the pressure overload model, FSP1 was primarily expressed by hematopoietic and vascular cells [18]. Multiple studies have raised similar concerns regarding the specificity of Col1a2-Cre to fibroblasts, which also express in many other parenchymal cell types, including epicardial cells and valvular interstitial cells [9,12,20]. Taken together, multiple studies have raised significant concerns about the specificity of FSP1 and COL1A2 as fibroblast markers. Due to these limitations, FSp1- or Col1a2-driven gene deletion is of limited value in the dissection of the role of FBs in the pathophysiology of cardiac diseases [18].
Presently, a growing consensus supports the notion that inducible transcription factor 21 (Tcf21)-MerCreMer (MCM) and periostin (Postn)-MCM mouse lines are the most reliable tools for fibroblast- or myofibroblast-specific gene targeting. Indeed, both the Postn-MCM and Tcf21-MCM are inducible; hence, gene deletion will only start once mice are subjected to Tamoxifen. Therefore, these new models avoid any unwanted confounding developmental effects. Periostin is a matricellular protein secreted by FBs. Periostin expression is negligible in the normal heart, while in the injured myocardium, periostin starts expressing in the FB population. Molkentin et al. [9] created a knock-in mouse (Postn-MCM), in which tamoxifen-inducible Cre recombinase expression cassette was inserted into the Postn gene locus. Their elegant report demonstrated that the Postn-MCM system could trace all the activated FBs/myofibroblasts in the injured heart, thus making this mouse line a valuable tool for myofibroblast-specific gene targeting. In addition to this targeted periostin knock-in model, a transgenic Postn-CreER2 was reported as well [21]. The key difference between the transgenic Cre driven by a fragment of the periostin promoter and knocking the Cre cassette into the periostin locus is that the expression of the Cre in the knock-in model represents the true endogenous regulation of periostin gene expression; whereas, the periostin-promoter-driven transgenic Cre may not have a complete set of regulatory information for that locus and thus does not fully represent the endogenous regulation. Since periostin expression is negligible-to-none in quiescent FBs, these animals are of limited value for FB-specific gene targeting in the healthy heart. This hurdle is overcome by the inducible Tcf21-MCM mouse model. TCF21 is a member of the bHLH (basic helix–loop–helix) family of transcription factors. It is expressed extensively during embryogenesis and it is essential to the development of cardiac FBs [20]. Importantly, in a healthy heart, a large number of resident fibroblasts are found to be TCF21+. Moreover, lineage-tracing experiments confirmed that TCF21+ cells are the primary source of myofibroblasts in the injured heart [9]. Taken together, these features enable the Tcf21-MCM system to target genes before cardiac injury and in all transient forms of FBs post-injury.
As noted above, traditionally, most of the research on fibroblast activation and fibrosis was centered on the canonical TGF-β signaling pathway [81,82,83]. However, the recent emergence of these conditional FB-specific mouse models has facilitated the identification of several additional novel pathways that are critical to fibroblast activation and fibrosis. Studies carried out with FB-specific, genetically manipulated mouse models are listed in Table 2. These pathways may operate independently or in co-ordination with TGF-β signaling. On the other hand, these updated tools have helped to redefine several hypotheses and concepts that exclusively relied on isolated culture models or mouse models that were later identified as non-specific. These included the views regarding the sources of FBs in the failing heart and the ability of activated fibroblasts to revert to the quiescent stage. Specifically, in complete disagreement with traditional beliefs, the new genetic models identified that most activated fibroblasts in the failing heart originate from existing resident fibroblasts, and activated fibroblasts can revert to the quiescent stage, once the stress is released [9,14]. These findings have enormous implications for human health; for example, the latter condition is directly comparable to that of patients with ventricular assistance devices (VAD). Furthermore, the discovery of fibroblast’s ability to revert to the quiescent stage opens the door to the potential reverse remodeling of fibrotic hearts.
In summary, the field of cardiac fibroblast and fibrosis research is going through a transition process. Traditional beliefs are being challenged, and novel pathways are being identified, leading to new and emerging concepts. This revolutionary transition is primarily driven by the emergence of newly developed, inducible, FB-specific mouse models. In the following sub-sections of this review article, we will specifically focus on the mechanisms of fibrosis that have been validated by multiple studies with FB-specific, in vivo mouse models.

2.1. TGF-β1 Signaling Pathway in Myocardial Fibrosis

The transforming growth factor-β (TGF-β) is a superfamily of 30 ligands that belongs to three main subfamilies: (1) TGF-β; (2) activins/inhibins/Nodal; and (3) bone morphogenetic proteins (BMPs). Among these, the TGF-β pathway has been considered a key mediator of fibroblast activation and fibrosis in the diseased heart [81,85]. There are three isoforms of TGF-β ligands: TGF-β1, TGF-β2, and TGF-β3. Despite having a remarkable homology, these ligands demonstrate distinct biological functions. In the canonical TGF-β signaling pathway, TGF-β ligands bind to Type II serine/threonine kinase receptors, which further trans-phosphorylate the Type I receptor’s kinase domain. These receptor kinases activate receptor-associated SMADs (R-SMADs), specifically SMAD2/3. Activated SMADs form a heteromeric complex with Co-SMAD, i.e., SMAD4. This complex translocates into the nucleus, binds to SMAD binding elements (SBE), and regulates the transcription of target genes. TGF-β signaling is negatively regulated by inhibitory SMADs (I-SMADs), namely SMAD6 and SMAD7. I-SMADs competitively inhibit R-SMADs activation at the Type I receptor or prevent the formation of the effector R-SMAD-Co-SMAD complex. Furthermore, I-SMADs are involved in the ubiquitination and degradation of Type I receptors [86,87]. In addition to the classical SMAD-dependent (canonical) pathway described above, TGF-βs act in a SMAD-independent manner (non-canonical) through non-canonical mediators, such as TGF-β-activated kinase 1 (TAK1), tumor necrosis factor (TNF), MAP kinases (ERK, p38, and JNK), Rho kinase, phosphoinositide 3-kinase (PI3K), AKT, and nuclear factor-κB (NF-κB) [88,89,90,91,92].
In order to investigate the fibroblast-specific role of canonical TGF-β signaling in the diseased heart, Khalil et al. [33] selectively deleted Tgfbr1/2, Smad2, or Smad3 using fibroblast specific Cre drivers. These authors observed that the fibroblast-specific double deletion of Tgfbr1/2 or Smad2/3 protected from TAC-induced myocardial fibrosis. Interestingly, the deletion of Smad2 alone did not affect adverse myocardial fibrosis, while Smad3 seemed to be indispensable to the pressure-overload-induced fibrotic response. Moreover, cardiac dysfunction and maladaptive hypertrophy were prevented in Tgfbr1/2 KOs, but deletion of Smad2, Smad3, Smad2/3 did not alter the ultimate decompensation of pressure-overloaded hearts. In contrast to this observation, Russo et al. [38] found that Smad3 deletion from activated fibroblast accelerated early systolic dysfunction after pressure overload. A difference in experimental design could explain this disparity between the cardiac phenotypes observed. Specifically, Russo et al. noticed cardiac dysfunction in Smad3 KOs during the adaptive phase of injury, when the SMAD3-dependent matrix preservation program is critical to protect the heart from injury. Khalil et al. missed this difference as they examined the effect of gene deletion at a later time point, i.e., during the advanced stage of cardiac disease. In the case of MI, myofibroblast-specific Smad3 deletion reduced collagen content, impaired scar organization, and increased the incidence of scar rupture and mortality [35]. In a transgenic mouse model of slow progressive genetic cardiomyopathy, myofibroblast-specific Tgfbr2 ablation at the early stage of disease progression reduced myocardial fibrosis, alleviated cardiac hypertrophy, improved cardiac function, and extended the lifespan of the diseased mice [36]. All these studies indicate that the FB-specific TGF-β signaling response varies considerably depending on context and plays a diverse role in the pathophysiology of cardiac diseases.

2.2. Co-Operation between Canonical Wnt/β-Catenin and TGF-β1-SMAD3 Signaling in Fibrosis

Glycogen synthase kinase-3 (GSK-3) is a family of ubiquitously expressed serine/threonine kinases. It was first identified in 1980 for its role in regulating glycogen synthase, the rate-limiting enzyme in glycogen synthesis [93]. The GSK-3 family consists of two isoforms, α, and β. These isoforms share a 98% homology in their kinase domains but differ substantially in their N- and C-terminal sequences [94,95]. The role of the GSK-3 family of kinases in cardiomyocyte biology is well established [96,97,98,99,100,101,102]. However, in vivo studies supporting the role of the GSK-3 family of kinases in myocardial fibrosis are just beginning to emerge [26]. We employed both Postn-Cre and Col1a2-Cre to investigate the role of cardiac fibroblast (CF) GSK-3β in myocardial fibrosis [26]. We reported that the CF-specific deletion of GSK-3β lead to excessive fibrogenesis, left ventricular dysfunction, and profound scarring in the infarcted heart. Mechanistically, GSK-3β deletion in cardiac fibroblasts caused the hyperactivation of SMAD3, resulting in excessive fibrosis [26]. In stark contrast, the FB-specific deletion of GSK-3α protected against TAC-induced myocardial fibrosis and cardiac dysfunction [44]. Interestingly, GSK-3α appears to promote fibrosis via the GSK-3α-ERK-IL-11 signaling circuit. We believe that GSK-3α-mediated pro-fibrotic signaling is among the few TGF-β1/SMAD3 independent pro-fibrotic signaling cascades identified to date. Future studies are warranted in order to further validate the GSK-3α-ERK-IL-11 signaling circuit as a therapeutic target for the management of myocardial fibrosis.
It is well recognized that GSK-3β plays an essential role in the Wnt/β-catenin signal transduction pathways [103]. The components and the molecular mechanism of Wnt/β-catenin signaling have been reviewed recently [104]. Briefly, in the absence of Wnt, GSK-3β participates in the destruction complex, where it phosphorylates β-catenin, leading to its ubiquitination and subsequent proteasomal degradation. However, the binding of Wnt ligands to frizzled receptors causes the disassembly of the destruction complex, thereby preventing GSK-3β mediated β-catenin phosphorylation and degradation. This leads to the stabilization and cytoplasmic accumulation of β-catenin, which further translocates into the nucleus and activates specific gene programs. Deb et al. [55] showed that acute ischemic injury induced Wnt1 expression in cardiac FBs and promoted cell proliferation in a β-catenin-dependent manner. To further confirm the biological relevance of Wnt/β-catenin signaling in adverse cardiac remodeling, they interrupted Wnt signaling by deleting β-catenin in FBs. This loss-of-function approach demonstrated minimal collagen deposition at the injury site with accelerated cardiac dysfunction and hypertrophy post-MI, suggesting that β-catenin-dependent signaling is required to maintain cardiac homeostasis in the ischemic heart. On the other hand, Xiang et al. [43] demonstrated that the loss of β-catenin in cardiac fibroblasts or myofibroblasts (Tcf21- or Postn-Cre) protects from pressure-overload-induced cardiac dysfunction and reduces interstitial fibrosis. These beneficial effects were seen despite the absence of any significant alteration in the FBs’ proliferation. However, β-catenin is known to interact with T-cell factor/lymphoid enhancer factor (TCF/LEF) gene sequences promoting the transcription of ECM genes. Nonetheless, the precise mechanism of the profibrotic role of GSK-3β-β-catenin signaling and its crosstalk with the TGF-β1 pathway is just beginning to emerge and needs further investigation [103] (Figure 1).

2.3. Molecular Mechanism of p38 MAPK Mediated Pro-Fibrotic Signaling

The mitogen-activated protein kinases (MAPKs) mediate a wide range of responses to extracellular stimuli and cell functions [105,106,107]. The MAPK family consists of four sub-families: extracellular signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK/SAPK), p38, and ERK/big MAP kinase 1 (ERK5/BMK1). The role of the ERK1/2 and JNK1/2/3 signaling cascade in myocardial fibrosis has not yet been studied with in vivo mouse models. Herein, we will discuss the role of p38 MAPK in myocardial fibrosis. There are four members in the p38 family: p38α (MAPK14/SAPK2a), p38β (MAPK11/SAPK2b), p38γ (MAPK12/SAPK3), and p38δ (MAPK13/SAPK4). Out of these, the p38α and p38β isoforms are ubiquitously expressed, while p38γ and p38δ expression varies, depending on the type of tissue [108].
Molkentin et al. provided the first direct evidence for the role of p38 in cardiac fibrosis [37]. They developed genetic mouse models in which p38α could be deleted from fibroblast or myofibroblast using tamoxifen-inducible Tcf21- and Postn- promoter-driven Cre recombinase, respectively. The deletion of p38α from the fibroblast prevented myofibroblast transformation and reduced fibrosis in two different mouse models of cardiac injury (IR and chronic neurohumoral-AngII stimulation). Fibroblast-specific p38α KO mice showed a higher incidence of scar rupture and 100% mortality after MI, thereby highlighting the critical role of this signaling axis in maintaining the structural integrity of the injured myocardium. Conversely, the expression of constitutively active p38α in fibroblast led to the development of cardiac fibrosis in transgenic mice, even in the absence of injury signals, further supporting the crucial role of p38α in fibrosis. In another study, Bageghni et al. [60] deleted p38α from fibroblast using tamoxifen-inducible Col1a2-Cre-ER(T) and observed protection against cardiac hypertrophy induced by isoproterenol (ꞵ-adrenergic receptor agonist). The authors further demonstrated that FB-p38α regulates cardiomyocyte hypertrophy in a paracrine manner through IL-6 secretion. Recently, the Davis group [30] engineered a biomimetic that recapitulates the spatial variations in collagen organization seen in ischemic hearts. Using this novel tool, the authors showed that topological disorganizations in the ECM lead to p38-dependent YAP stabilization in FBs. Indeed, YAP promotes myofibroblast transformation and myocardial fibrosis. Taken together, the p38 MAPK signaling is among the best-characterized positive regulators of fibroblast activation and myocardial fibrosis (Figure 2).

2.4. GPCR-Mediated Myocardial Pro-Fibrotic Signaling

G-protein-coupled receptors (GPCRs) signaling has been extensively linked with the pathogenesis of cardiac diseases. Many conventional therapies for HF, such as beta-blockers and angiotensin-II receptor blockers (ARBs) work by targeting GPCRs. GPCRs represent the largest family of transmembrane receptors. In classical GPCR signaling, the binding of ligands induces conformational changes in the receptor, thereby activating G protein and inducing intracellular signaling cascades. The G-protein-coupled receptor kinases (GRK) are the negative regulators of GPCR signaling. Specifically, GRKs phosphorylate ligand-bound GPCRs and create a docking site for ꞵ-arrestin. This high-affinity binding of ꞵ-arrestin leads to the desensitization or downregulation of GPCRs. GRKs are a family of serine/threonine kinases. Based on tissue specificity and sequence homology, GRKs are further classified into 3 subfamilies: rhodopsin kinases (GRKs 1 and 7); β-adrenergic receptor kinases (GRKs 2 and 3); and the GRK4 subfamily (GRKs 4, 5, and 6) [109,110,111]. In the heart, the expression of GRK2 and GRK5 isoforms is predominant. A large body of research adequately supports a central role for cardiomyocyte GRKs in the pathogenesis of cardiac diseases [112,113]. However, studies investigating the FB-specific role of GRKs in cardiac diseases are limited.
To determine the role of cardiac fibroblast GRK2 in myocardial fibrosis, Koch et al. employed inducible fibroblast-specific GRK2 KOs [62]. Indeed, cardiac fibroblast GRK2 deletion protected against ischemia/reperfusion (I/R)-induced cardiac injury and adverse remodeling [62]. Consistently, pharmacological inhibition or the targeting of GRK2 in activated fibroblast attenuated pathological myofibroblast activation, interstitial fibrosis, and HF progression [42]. These protective effects were associated with a reduction in fibrotic and inflammatory responses in the re-perfused hearts. Mechanistically, it was proposed that GRK2 mediates pro-fibrotic effects by modulating cAMP levels in fibroblasts. Furthermore, GRK2 acts as a positive regulator of NF-κB signaling and promotes inflammatory cytokine secretion in the ischemic heart. The Koch laboratory employed two different mouse models, specifically MI and in vivo AngII infusion, to investigate the fibroblast-specific role of GRK5 in the pathogenesis of cardiac diseases. In both models, the FB-specific deletion of GRK5 prevented adverse cardiac remodeling and improved systolic function. Furthermore, the authors demonstrated that non-canonical interaction between GRK5 and NFAT potentiates NFAT: DNA binding, thereby inducing the transcription of NFAT-mediated fibrotic genes [58]. Additionally, the activation of β2-adrenergic receptors (β2AR) leads to the proliferation of cardiac proliferation and fibrosis through the Gαs/ERK1/2-dependent IL-6 secretion [114]. However, the role of β2AR in cardiac fibrosis needs further validation with conditional FB-specific mouse models in an in vivo setting. Taken together, GPCRs-mediated signaling, specifically β2AR, GRK2, and GRK5, is the critical positive regulator of myocardial fibrosis, therefore representing a novel therapeutic target for the limitation of excessive myofibroblast activation and interstitial fibrosis in the diseased heart (Figure 3).

2.5. Hippo Signaling Pathway in Myocardial Fibrosis

The Hippo signaling pathway was first identified in Drosophila and was found to be evolutionary conserved. It controls organ size by regulating cell proliferation and apoptosis [115,116,117]. The Hippo signaling network is complex as it operates with more than 30 different components. In mammals, this signaling initiates at the mammalian Ste20-like kinases (MST1/2), which are orthologous to Drosophila Hippo. MST1/2 forms a complex with adaptor protein, a Sav family WW domain-containing protein 1 (SAV1) that allows the phosphorylation/activation of the large tumor suppressor 1/2 (LATS 1/2). LATS 1/2 regulates the transcriptional activities of two transcriptional co-activators, yes-associated protein (YAP) and the transcriptional co-activator with PDZ-binding motif (TAZ). When the pathway is active, LATS 1/2 phosphorylates YAP and TAZ, thereby sequestering them in the cytoplasm, eventually leading to their ubiquitin-mediated proteasomal degradation. However, the inactivation of this pathway permits the stabilization and nuclear translocation of YAP and TAZ, whereupon they interact with the TEA domain family (TEAD1-4) of transcription factors and enhance the expression of target genes [115,116,117]. Mechanotransduction plays an important role in the determining the subcellular localization of YAP/TAZ. Specifically, ECM elasticity and Rho ATPase-mediated cytoskeleton dynamics have been linked to YAP/TAZ activation [118,119].
The Hippo pathway plays a critical role in cardiac development, cardiomyocyte biology, and regeneration, which has recently been elegantly reviewed [120]. Herein, we will exclusively focus on in vivo studies with FB-specific mouse models investigating the role of this signaling in fibroblast biology and fibrosis. Fransisco et al. [46] showed that YAP expression increased in FBs after MI, and FB-specific YAP ablation attenuated MI-induced cardiac dysfunction and fibrosis. The authors further demonstrated that YAP promoted myofibroblast differentiation and ECM gene expression through MRTF-A. Martin’s laboratory demonstrated that Hippo signaling promoted epicardial progenitors to fibroblast transition during embryonic development [121]. In another study, the same group conditionally deleted the Hippo pathway kinases LATS1 and LATS2 from adult mouse cardiac fibroblasts. Interestingly, the ablation of LATS1/2 from adult resting cardiac FBs caused spontaneous myofibroblast transformation, cardiac fibrosis, and systolic dysfunction, even in the absence of any cardiac insult. Moreover, the basal fibrotic response (without injury) became more severe in LATS1/2 KOs post-MI, resulting in a poor survival rate. The authors of this study employed single-cell transcriptome analysis and demonstrated that LATS1/2 are essential to the maintenance of FBs in the resting state [47]. These findings are important since there is a general belief that fibroblasts have a minimal role in resting heart physiology. Indeed, most of the research on myocardial fibrosis is limited to diseased conditions. Thus, future investigations are needed to identify the physiological role of fibroblasts in the healthy heart (Figure 4).

3. Conclusions and Future Perspectives

As discussed throughout this review, the recent emergence of the conditional FB-specific mouse model revolutionized the area of cardiac fibroblast biology and myocardial fibrosis research. As a result, the last decade was productive, leading to a paradigm shift towards the idea that fibrosis is not merely a secondary effect of developing pathology and that fibroblasts are not just ECM-producing cells. In fact, numerous studies showed that FB-specific gene targeting can lead to a robust cardiac phenotype, including cardiomyocyte hypertrophy. Indeed, the animals studied demonstrated intact gene expression in all other cells, including the cardiomyocytes. Thus, the last decade saw remarkable progress in our understanding of cardiac fibroblasts’ role in myocardial pathophysiology. There was reasonable success on the mechanism front as well; in addition to the historical profibrotic canonical TGF-β1 pathway, numerous new pro- and anti-fibrotic pathways were identified. However, although substantial progress has been made, it will require a great deal of effort to transform these early bench discoveries into much-needed anti-fibrotic therapies for patients. Specifically, most of the work performed is focused on linear pathways; it is conceivable that these newly identified pathways operate through multiple crosstalk. These signaling circuits and missing links are yet to be established. An upcoming area of enormous potential is the cellular crosstalk among cardiac cells (e.g., fibroblasts to cardiomyocytes) and the circulation (immune cells). The area of fibroblast crosstalk with the immune system and its role in myocardial injury, healing, regeneration, and fibrosis is gaining a lot of interest and is currently under intense investigation by multiple groups. Furthermore, the interplay of fibroblast and inflammation is proposed to play a critical role in the pathogenesis of the comparatively understudied HFpEF syndrome. Regrettably, due to the lack of well-optimized animal models of HFpEF, the progress in this exciting area has been slow and is only just starting to gain some momentum. In the same vein, cardiomyocytes and fibroblast cellular crosstalk has been noted in multiple settings. However, the precise mechanism is not known and is currently under intense investigation by numerous groups. Another emerging area is fibroblast heterogeneity within organs and across various tissues. This line of research with single-cell multi-omics and advanced genomics technologies will be critical to the identification of commonalities and heterogeneity among fibrotic diseases across organs and could play a crucial role in drug repurposing. Indeed, we have recently reported the potential of repurposing Nintedanib (an FDA-approved kinase inhibitor for pulmonary fibrosis) to combat myocardial fibrosis, pathological cardiac remodeling, and dysfunction [122]. The repurposing of authorized anti-fibrotic agents is certainly a “low hanging fruit,” and this line of investigation should be prioritized. Moreover, we anticipate that various fibroblast subpopulations may have a distinct role in the repair and remodeling of the injured heart. Efforts from multiple laboratories with the single-cell RNAseq approach have paved the way towards the identification of the specific markers of different fibroblast subpopulations. We speculate that this knowledge base will help to create future FB-specific mouse models with the ability to target particular FB subpopulations. Finally, it is clear that a better understanding of the profibrotic signaling network may provide a promising new therapeutic target for managing myocardial fibrosis. An effective translation of these new findings will need rigorous verification in human tissues and human tissue-based culture systems, such as pluripotent cell-derived organoids (human tissue chips). There is great optimism that with these newly optimized models and identified pathways, the area of myocardial fibrosis research is set to see another round of growth and productivity. We anticipate that these efforts will enable new approaches to the prevention, treatment, and, hopefully, even the reversal of myocardial fibrosis in diseased hearts.

Author Contributions

Conceptualization: H.L. and P.U.; Investigation: H.L. and P.U.; original draft preparation: H.L., P.U. and S.E.; review and editing: H.L., P.U., S.E. and S.T.; funding acquisition: H.L. and P.U. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by research grants from the NHLBI (R01HL133290 and 5R01HL143074-03) to H.L., P.U. was supported by American Heart Association (19POST34460025).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

We apologize to those whose original work could not be cited owing to space limitations.

Conflicts of Interest

The authors have no conflicting interests to disclose in relation to this work.

References

  1. Kramann, R.; Schneider, R.K.; DiRocco, D.P.; Machado, F.; Fleig, S.; Bondzie, P.A.; Henderson, J.M.; Ebert, B.L.; Humphreys, B.D. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 2015, 16, 51–66. [Google Scholar] [CrossRef] [Green Version]
  2. Ieronimakis, N.; Hays, A.L.; Janebodin, K.; Mahoney, W.M., Jr.; Duffield, J.S.; Majesky, M.W.; Reyes, M. Coronary adventitial cells are linked to perivascular cardiac fibrosis via TGFbeta1 signaling in the mdx mouse model of Duchenne muscular dystrophy. J. Mol. Cell. Cardiol. 2013, 63, 122–134. [Google Scholar] [CrossRef] [Green Version]
  3. Van Wijk, B.; Gunst, Q.D.; Moorman, A.F.; van den Hoff, M.J. Cardiac regeneration from activated epicardium. PLoS ONE 2012, 7, e44692. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Zhou, B.; Honor, L.B.; He, H.; Ma, Q.; Oh, J.H.; Butterfield, C.; Lin, R.Z.; Melero-Martin, J.M.; Dolmatova, E.; Duffy, H.S.; et al. Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J. Clin. Investig. 2011, 121, 1894–1904. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Widyantoro, B.; Emoto, N.; Nakayama, K.; Anggrahini, D.W.; Adiarto, S.; Iwasa, N.; Yagi, K.; Miyagawa, K.; Rikitake, Y.; Suzuki, T.; et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010, 121, 2407–2418. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Zeisberg, E.M.; Tarnavski, O.; Zeisberg, M.; Dorfman, A.L.; McMullen, J.R.; Gustafsson, E.; Chandraker, A.; Yuan, X.; Pu, W.T.; Roberts, A.B.; et al. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat. Med. 2007, 13, 952–961. [Google Scholar] [CrossRef]
  7. Haudek, S.B.; Xia, Y.; Huebener, P.; Lee, J.M.; Carlson, S.; Crawford, J.R.; Pilling, D.; Gomer, R.H.; Trial, J.; Frangogiannis, N.G.; et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc. Natl. Acad. Sci. USA 2006, 103, 18284–18289. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Mollmann, H.; Nef, H.M.; Kostin, S.; von Kalle, C.; Pilz, I.; Weber, M.; Schaper, J.; Hamm, C.W.; Elsasser, A. Bone marrow-derived cells contribute to infarct remodelling. Cardiovasc. Res. 2006, 71, 661–671. [Google Scholar] [CrossRef]
  9. Kanisicak, O.; Khalil, H.; Ivey, M.J.; Karch, J.; Maliken, B.D.; Correll, R.N.; Brody, M.J.; SC, J.L.; Aronow, B.J.; Tallquist, M.D.; et al. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nat. Commun. 2016, 7, 12260. [Google Scholar] [CrossRef] [Green Version]
  10. Ruiz-Villalba, A.; Simon, A.M.; Pogontke, C.; Castillo, M.I.; Abizanda, G.; Pelacho, B.; Sanchez-Dominguez, R.; Segovia, J.C.; Prosper, F.; Perez-Pomares, J.M. Interacting resident epicardium-derived fibroblasts and recruited bone marrow cells form myocardial infarction scar. J. Am. Coll. Cardiol. 2015, 65, 2057–2066. [Google Scholar] [CrossRef] [Green Version]
  11. Ali, S.R.; Ranjbarvaziri, S.; Talkhabi, M.; Zhao, P.; Subat, A.; Hojjat, A.; Kamran, P.; Muller, A.M.; Volz, K.S.; Tang, Z.; et al. Developmental heterogeneity of cardiac fibroblasts does not predict pathological proliferation and activation. Circ. Res. 2014, 115, 625–635. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Moore-Morris, T.; Guimaraes-Camboa, N.; Banerjee, I.; Zambon, A.C.; Kisseleva, T.; Velayoudon, A.; Stallcup, W.B.; Gu, Y.; Dalton, N.D.; Cedenilla, M.; et al. Resident fibroblast lineages mediate pressure overload-induced cardiac fibrosis. J. Clin. Investig. 2014, 124, 2921–2934. [Google Scholar] [CrossRef] [Green Version]
  13. Tallquist, M.D. Cardiac Fibroblast Diversity. Annu. Rev. Physiol. 2020, 82, 63–78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Fu, X.; Khalil, H.; Kanisicak, O.; Boyer, J.G.; Vagnozzi, R.J.; Maliken, B.D.; Sargent, M.A.; Prasad, V.; Valiente-Alandi, I.; Blaxall, B.C.; et al. Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart. J. Clin. Investig. 2018, 128, 2127–2143. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Tallquist, M.D.; Molkentin, J.D. Redefining the identity of cardiac fibroblasts. Nat. Rev. Cardiol. 2017, 14, 484–491. [Google Scholar] [CrossRef] [PubMed]
  16. Ma, Y.; Iyer, R.P.; Jung, M.; Czubryt, M.P.; Lindsey, M.L. Cardiac Fibroblast Activation Post-Myocardial Infarction: Current Knowledge Gaps. Trends Pharmacol. Sci. 2017, 38, 448–458. [Google Scholar] [CrossRef] [Green Version]
  17. Bhowmick, N.A.; Chytil, A.; Plieth, D.; Gorska, A.E.; Dumont, N.; Shappell, S.; Washington, M.K.; Neilson, E.G.; Moses, H.L. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004, 303, 848–851. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. Kong, P.; Christia, P.; Saxena, A.; Su, Y.; Frangogiannis, N.G. Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis. Am. J. Physiol. Heart Circ. Physiol. 2013, 305, H1363–H1372. [Google Scholar] [CrossRef]
  19. Osterreicher, C.H.; Penz-Osterreicher, M.; Grivennikov, S.I.; Guma, M.; Koltsova, E.K.; Datz, C.; Sasik, R.; Hardiman, G.; Karin, M.; Brenner, D.A. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc. Natl. Acad. Sci. USA 2011, 108, 308–313. [Google Scholar] [CrossRef] [Green Version]
  20. Acharya, A.; Baek, S.T.; Huang, G.; Eskiocak, B.; Goetsch, S.; Sung, C.Y.; Banfi, S.; Sauer, M.F.; Olsen, G.S.; Duffield, J.S.; et al. The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development 2012, 139, 2139–2149. [Google Scholar] [CrossRef] [Green Version]
  21. Kaur, H.; Takefuji, M.; Ngai, C.Y.; Carvalho, J.; Bayer, J.; Wietelmann, A.; Poetsch, A.; Hoelper, S.; Conway, S.J.; Mollmann, H.; et al. Targeted Ablation of Periostin-Expressing Activated Fibroblasts Prevents Adverse Cardiac Remodeling in Mice. Circ. Res. 2016, 118, 1906–1917. [Google Scholar] [CrossRef] [Green Version]
  22. Ivey, M.J.; Tallquist, M.D. Defining the Cardiac Fibroblast. Circ. J. 2016, 80, 2269–2276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Swonger, J.M.; Liu, J.S.; Ivey, M.J.; Tallquist, M.D. Genetic tools for identifying and manipulating fibroblasts in the mouse. Differentiation 2016, 92, 66–83. [Google Scholar] [CrossRef] [Green Version]
  24. Mohamed, T.M.A.; Abou-Leisa, R.; Stafford, N.; Maqsood, A.; Zi, M.; Prehar, S.; Baudoin-Stanley, F.; Wang, X.; Neyses, L.; Cartwright, E.J.; et al. The plasma membrane calcium ATPase 4 signalling in cardiac fibroblasts mediates cardiomyocyte hypertrophy. Nat. Commun. 2016, 7, 11074. [Google Scholar] [CrossRef] [PubMed]
  25. Travers, J.G.; Kamal, F.A.; Robbins, J.; Yutzey, K.E.; Blaxall, B.C. Cardiac Fibrosis: The Fibroblast Awakens. Circ. Res. 2016, 118, 1021–1040. [Google Scholar] [CrossRef] [Green Version]
  26. Lal, H.; Ahmad, F.; Zhou, J.; Yu, J.E.; Vagnozzi, R.J.; Guo, Y.; Yu, D.; Tsai, E.J.; Woodgett, J.; Gao, E.; et al. Cardiac fibroblast glycogen synthase kinase-3beta regulates ventricular remodeling and dysfunction in ischemic heart. Circulation 2014, 130, 419–430. [Google Scholar] [CrossRef] [PubMed]
  27. Takeda, N.; Manabe, I.; Uchino, Y.; Eguchi, K.; Matsumoto, S.; Nishimura, S.; Shindo, T.; Sano, M.; Otsu, K.; Snider, P.; et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Investig. 2010, 120, 254–265. [Google Scholar] [CrossRef] [Green Version]
  28. Snider, P.; Standley, K.N.; Wang, J.; Azhar, M.; Doetschman, T.; Conway, S.J. Origin of cardiac fibroblasts and the role of periostin. Circ. Res. 2009, 105, 934–947. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Oka, T.; Xu, J.; Kaiser, R.A.; Melendez, J.; Hambleton, M.; Sargent, M.A.; Lorts, A.; Brunskill, E.W.; Dorn, G.W., 2nd; Conway, S.J.; et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ. Res. 2007, 101, 313–321. [Google Scholar] [CrossRef] [Green Version]
  30. Bugg, D.; Bretherton, R.; Kim, P.; Olszewski, E.; Nagle, A.; Schumacher, A.E.; Chu, N.; Gunaje, J.; DeForest, C.A.; Stevens, K.; et al. Infarct Collagen Topography Regulates Fibroblast Fate via p38-Yes-Associated Protein Transcriptional Enhanced Associate Domain Signals. Circ. Res. 2020, 127, 1306–1322. [Google Scholar] [CrossRef] [PubMed]
  31. Davis, J.; Salomonis, N.; Ghearing, N.; Lin, S.C.; Kwong, J.Q.; Mohan, A.; Swanson, M.S.; Molkentin, J.D. MBNL1-mediated regulation of differentiation RNAs promotes myofibroblast transformation and the fibrotic response. Nat. Commun. 2015, 6, 10084. [Google Scholar] [CrossRef] [Green Version]
  32. Dufeys, C.; Daskalopoulos, E.P.; Castanares-Zapatero, D.; Conway, S.J.; Ginion, A.; Bouzin, C.; Ambroise, J.; Bearzatto, B.; Gala, J.L.; Heymans, S.; et al. AMPKalpha1 deletion in myofibroblasts exacerbates post-myocardial infarction fibrosis by a connexin 43 mechanism. Basic Res. Cardiol. 2021, 116, 10. [Google Scholar] [CrossRef]
  33. Khalil, H.; Kanisicak, O.; Prasad, V.; Correll, R.N.; Fu, X.; Schips, T.; Vagnozzi, R.J.; Liu, R.; Huynh, T.; Lee, S.J.; et al. Fibroblast-specific TGF-beta-Smad2/3 signaling underlies cardiac fibrosis. J. Clin. Investig. 2017, 127, 3770–3783. [Google Scholar] [CrossRef]
  34. Khalil, H.; Kanisicak, O.; Vagnozzi, R.J.; Johansen, A.K.; Maliken, B.D.; Prasad, V.; Boyer, J.G.; Brody, M.J.; Schips, T.; Kilian, K.K.; et al. Cell-specific ablation of Hsp47 defines the collagen-producing cells in the injured heart. JCI Insight 2019, 4, e128722. [Google Scholar] [CrossRef]
  35. Kong, P.; Shinde, A.V.; Su, Y.; Russo, I.; Chen, B.; Saxena, A.; Conway, S.J.; Graff, J.M.; Frangogiannis, N.G. Opposing Actions of Fibroblast and Cardiomyocyte Smad3 Signaling in the Infarcted Myocardium. Circulation 2018, 137, 707–724. [Google Scholar] [CrossRef]
  36. Meng, Q.; Bhandary, B.; Bhuiyan, M.S.; James, J.; Osinska, H.; Valiente-Alandi, I.; Shay-Winkler, K.; Gulick, J.; Molkentin, J.D.; Blaxall, B.C.; et al. Myofibroblast-Specific TGFbeta Receptor II Signaling in the Fibrotic Response to Cardiac Myosin Binding Protein C-Induced Cardiomyopathy. Circ. Res. 2018, 123, 1285–1297. [Google Scholar] [CrossRef] [PubMed]
  37. Molkentin, J.D.; Bugg, D.; Ghearing, N.; Dorn, L.E.; Kim, P.; Sargent, M.A.; Gunaje, J.; Otsu, K.; Davis, J. Fibroblast-Specific Genetic Manipulation of p38 Mitogen-Activated Protein Kinase In Vivo Reveals Its Central Regulatory Role in Fibrosis. Circulation 2017, 136, 549–561. [Google Scholar] [CrossRef] [PubMed]
  38. Russo, I.; Cavalera, M.; Huang, S.; Su, Y.; Hanna, A.; Chen, B.; Shinde, A.V.; Conway, S.J.; Graff, J.; Frangogiannis, N.G. Protective Effects of Activated Myofibroblasts in the Pressure-Overloaded Myocardium Are Mediated Through Smad-Dependent Activation of a Matrix-Preserving Program. Circ. Res. 2019, 124, 1214–1227. [Google Scholar] [CrossRef] [PubMed]
  39. Scharf, G.M.; Kilian, K.; Cordero, J.; Wang, Y.; Grund, A.; Hofmann, M.; Froese, N.; Wang, X.; Kispert, A.; Kist, R.; et al. Inactivation of Sox9 in fibroblasts reduces cardiac fibrosis and inflammation. JCI Insight 2019, 5, e126721. [Google Scholar] [CrossRef]
  40. Shimizu, T.; Narang, N.; Chen, P.; Yu, B.; Knapp, M.; Janardanan, J.; Blair, J.; Liao, J.K. Fibroblast deletion of ROCK2 attenuates cardiac hypertrophy, fibrosis, and diastolic dysfunction. JCI Insight 2017, 2, e93187. [Google Scholar] [CrossRef]
  41. Snider, J.C.; Riley, L.A.; Mallory, N.T.; Bersi, M.R.; Umbarkar, P.; Gautam, R.; Zhang, Q.; Mahadevan-Jansen, A.; Hatzopoulos, A.K.; Maroteaux, L.; et al. Targeting 5-HT2B Receptor Signaling Prevents Border Zone Expansion and Improves Microstructural Remodeling After Myocardial Infarction. Circulation 2021, 143, 1317–1330. [Google Scholar] [CrossRef] [PubMed]
  42. Travers, J.G.; Kamal, F.A.; Valiente-Alandi, I.; Nieman, M.L.; Sargent, M.A.; Lorenz, J.N.; Molkentin, J.D.; Blaxall, B.C. Pharmacological and Activated Fibroblast Targeting of Gbetagamma-GRK2 After Myocardial Ischemia Attenuates Heart Failure Progression. J. Am. Coll. Cardiol. 2017, 70, 958–971. [Google Scholar] [CrossRef] [PubMed]
  43. Xiang, F.L.; Fang, M.; Yutzey, K.E. Loss of beta-catenin in resident cardiac fibroblasts attenuates fibrosis induced by pressure overload in mice. Nat. Commun. 2017, 8, 712. [Google Scholar] [CrossRef]
  44. Umbarkar, P.; Tousif, S.; Singh, A.P.; Anderson, J.C.; Zhang, Q.; Lal, H. Cardiac fibroblast GSK-3α mediates adverse myocardial fibrosis via IL-11 and ERK pathway. bioRxiv 2021. [Google Scholar] [CrossRef]
  45. Pinto, A.R.; Ilinykh, A.; Ivey, M.J.; Kuwabara, J.T.; D′Antoni, M.L.; Debuque, R.; Chandran, A.; Wang, L.; Arora, K.; Rosenthal, N.A.; et al. Revisiting Cardiac Cellular Composition. Circ. Res. 2016, 118, 400–409. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Francisco, J.; Zhang, Y.; Jeong, J.I.; Mizushima, W.; Ikeda, S.; Ivessa, A.; Oka, S.; Zhai, P.; Tallquist, M.D.; Del Re, D.P. Blockade of Fibroblast YAP Attenuates Cardiac Fibrosis and Dysfunction Through MRTF-A Inhibition. JACC Basic Transl. Sci. 2020, 5, 931–945. [Google Scholar] [CrossRef]
  47. Xiao, Y.; Hill, M.C.; Li, L.; Deshmukh, V.; Martin, T.J.; Wang, J.; Martin, J.F. Hippo pathway deletion in adult resting cardiac fibroblasts initiates a cell state transition with spontaneous and self-sustaining fibrosis. Genes. Dev. 2019, 33, 1491–1505. [Google Scholar] [CrossRef] [Green Version]
  48. Abraham, D.M.; Lee, T.E.; Watson, L.J.; Mao, L.; Chandok, G.; Wang, H.G.; Frangakis, S.; Pitt, G.S.; Shah, S.H.; Wolf, M.J.; et al. The two-pore domain potassium channel TREK-1 mediates cardiac fibrosis and diastolic dysfunction. J. Clin. Investig. 2018, 128, 4843–4855. [Google Scholar] [CrossRef] [Green Version]
  49. Valiente-Alandi, I.; Potter, S.J.; Salvador, A.M.; Schafer, A.E.; Schips, T.; Carrillo-Salinas, F.; Gibson, A.M.; Nieman, M.L.; Perkins, C.; Sargent, M.A.; et al. Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure. Circulation 2018, 138, 1236–1252. [Google Scholar] [CrossRef]
  50. Clement, S.; Stouffs, M.; Bettiol, E.; Kampf, S.; Krause, K.H.; Chaponnier, C.; Jaconi, M. Expression and function of alpha-smooth muscle actin during embryonic-stem-cell-derived cardiomyocyte differentiation. J. Cell Sci. 2007, 120, 229–238. [Google Scholar] [CrossRef] [Green Version]
  51. Bursac, N. Cardiac fibroblasts in pressure overload hypertrophy: The enemy within? J. Clin. Investig. 2014, 124, 2850–2853. [Google Scholar] [CrossRef] [Green Version]
  52. Hudon-David, F.; Bouzeghrane, F.; Couture, P.; Thibault, G. Thy-1 expression by cardiac fibroblasts: Lack of association with myofibroblast contractile markers. J. Mol. Cell. Cardiol. 2007, 42, 991–1000. [Google Scholar] [CrossRef]
  53. Vitetta, E.S.; Boyse, E.A.; Uhr, J.W. Isolation and characterization of a molecular complex containing Thy-1 antigen from the surface of murine thymocytes and T cells. Eur. J. Immunol. 1973, 3, 446–453. [Google Scholar] [CrossRef] [PubMed]
  54. Ubil, E.; Duan, J.; Pillai, I.C.; Rosa-Garrido, M.; Wu, Y.; Bargiacchi, F.; Lu, Y.; Stanbouly, S.; Huang, J.; Rojas, M.; et al. Mesenchymal-endothelial transition contributes to cardiac neovascularization. Nature 2014, 514, 585–590. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Duan, J.; Gherghe, C.; Liu, D.; Hamlett, E.; Srikantha, L.; Rodgers, L.; Regan, J.N.; Rojas, M.; Willis, M.; Leask, A.; et al. Wnt1/betacatenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO J. 2012, 31, 429–442. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Baum, J.; Duffy, H.S. Fibroblasts and myofibroblasts: What are we talking about? J. Cardiovasc. Pharmacol. 2011, 57, 376–379. [Google Scholar] [CrossRef] [PubMed]
  57. Zheng, B.; Zhang, Z.; Black, C.M.; de Crombrugghe, B.; Denton, C.P. Ligand-dependent genetic recombination in fibroblasts: A potentially powerful technique for investigating gene function in fibrosis. Am. J. Pathol. 2002, 160, 1609–1617. [Google Scholar] [CrossRef]
  58. Eguchi, A.; Coleman, R.; Gresham, K.; Gao, E.; Ibetti, J.; Chuprun, J.K.; Koch, W.J. GRK5 is a regulator of fibroblast activation and cardiac fibrosis. Proc. Natl. Acad. Sci. USA 2021, 118, e2012854118. [Google Scholar] [CrossRef]
  59. Bageghni, S.A.; Hemmings, K.E.; Yuldasheva, N.Y.; Maqbool, A.; Gamboa-Esteves, F.O.; Humphreys, N.E.; Jackson, M.S.; Denton, C.P.; Francis, S.; Porter, K.E.; et al. Fibroblast-specific deletion of interleukin-1 receptor-1 reduces adverse cardiac remodeling following myocardial infarction. JCI Insight 2019, 5, e125074. [Google Scholar] [CrossRef] [Green Version]
  60. Bageghni, S.A.; Hemmings, K.E.; Zava, N.; Denton, C.P.; Porter, K.E.; Ainscough, J.F.X.; Drinkhill, M.J.; Turner, N.A. Cardiac fibroblast-specific p38alpha MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism. FASEB J. 2018, 32, 4941–4954. [Google Scholar] [CrossRef] [Green Version]
  61. Li, Y.; Li, Z.; Zhang, C.; Li, P.; Wu, Y.; Wang, C.; Bond Lau, W.; Ma, X.L.; Du, J. Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling. Circulation 2017, 135, 2041–2057. [Google Scholar] [CrossRef] [PubMed]
  62. Woodall, M.C.; Woodall, B.P.; Gao, E.; Yuan, A.; Koch, W.J. Cardiac Fibroblast GRK2 Deletion Enhances Contractility and Remodeling Following Ischemia/Reperfusion Injury. Circ. Res. 2016, 119, 1116–1127. [Google Scholar] [CrossRef] [Green Version]
  63. DeLeon-Pennell, K.Y. May the fibrosis be with you: Is discoidin domain receptor 2 the receptor we have been looking for? J. Mol. Cell Cardiol. 2016, 91, 201–203. [Google Scholar] [CrossRef] [PubMed]
  64. Cowling, R.T.; Yeo, S.J.; Kim, I.J.; Park, J.I.; Gu, Y.; Dalton, N.D.; Peterson, K.L.; Greenberg, B.H. Discoidin domain receptor 2 germline gene deletion leads to altered heart structure and function in the mouse. Am. J. Physiol. Heart Circ. Physiol. 2014, 307, H773–H781. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Morales, M.O.; Price, R.L.; Goldsmith, E.C. Expression of Discoidin Domain Receptor 2 (DDR2) in the developing heart. Microsc. Microanal. 2005, 11, 260–267. [Google Scholar] [CrossRef]
  66. Strutz, F.; Okada, H.; Lo, C.W.; Danoff, T.; Carone, R.L.; Tomaszewski, J.E.; Neilson, E.G. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 1995, 130, 393–405. [Google Scholar] [CrossRef] [Green Version]
  67. Zhang, X.; Yuan, S.; Li, H.; Zhan, J.; Wang, F.; Fan, J.; Nie, X.; Wang, Y.; Wen, Z.; Chen, Y.; et al. The double face of miR-320: Cardiomyocytes-derived miR-320 deteriorated while fibroblasts-derived miR-320 protected against heart failure induced by transverse aortic constriction. Signal Transduct. Target. Ther. 2021, 6, 69. [Google Scholar] [CrossRef] [PubMed]
  68. Bagchi, R.A.; Lin, J.; Wang, R.; Czubryt, M.P. Regulation of fibronectin gene expression in cardiac fibroblasts by scleraxis. Cell Tissue Res. 2016, 366, 381–391. [Google Scholar] [CrossRef] [PubMed]
  69. Souders, C.A.; Bowers, S.L.; Baudino, T.A. Cardiac fibroblast: The renaissance cell. Circ. Res. 2009, 105, 1164–1176. [Google Scholar] [CrossRef] [PubMed]
  70. Philips, N.; Bashey, R.I.; Jimenez, S.A. Collagen and fibronectin expression in cardiac fibroblasts from hypertensive rats. Cardiovasc. Res. 1994, 28, 1342–1347. [Google Scholar] [CrossRef]
  71. Miwa, H.; Era, T. Generation and characterization of PDGFRalpha-GFPCreERT2 knock-In mouse line. Genesis 2015, 53, 329–336. [Google Scholar] [CrossRef]
  72. Chong, J.J.; Reinecke, H.; Iwata, M.; Torok-Storb, B.; Stempien-Otero, A.; Murry, C.E. Progenitor cells identified by PDGFR-alpha expression in the developing and diseased human heart. Stem Cells Dev. 2013, 22, 1932–1943. [Google Scholar] [CrossRef] [Green Version]
  73. Smith, C.L.; Baek, S.T.; Sung, C.Y.; Tallquist, M.D. Epicardial-derived cell epithelial-to-mesenchymal transition and fate specification require PDGF receptor signaling. Circ. Res. 2011, 108, e15–e26. [Google Scholar] [CrossRef] [PubMed]
  74. Furtado, M.B.; Costa, M.W.; Pranoto, E.A.; Salimova, E.; Pinto, A.R.; Lam, N.T.; Park, A.; Snider, P.; Chandran, A.; Harvey, R.P.; et al. Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circ. Res. 2014, 114, 1422–1434. [Google Scholar] [CrossRef] [PubMed]
  75. McQualter, J.L.; Brouard, N.; Williams, B.; Baird, B.N.; Sims-Lucas, S.; Yuen, K.; Nilsson, S.K.; Simmons, P.J.; Bertoncello, I. Endogenous fibroblastic progenitor cells in the adult mouse lung are highly enriched in the sca-1 positive cell fraction. Stem Cells 2009, 27, 623–633. [Google Scholar] [CrossRef] [PubMed]
  76. Wang, X.; Hu, Q.; Nakamura, Y.; Lee, J.; Zhang, G.; From, A.H.; Zhang, J. The role of the sca-1+/CD31- cardiac progenitor cell population in postinfarction left ventricular remodeling. Stem Cells 2006, 24, 1779–1788. [Google Scholar] [CrossRef]
  77. Cheng, F.; Shen, Y.; Mohanasundaram, P.; Lindstrom, M.; Ivaska, J.; Ny, T.; Eriksson, J.E. Vimentin coordinates fibroblast proliferation and keratinocyte differentiation in wound healing via TGF-beta-Slug signaling. Proc. Natl. Acad. Sci. USA 2016, 113, E4320–E4327. [Google Scholar] [CrossRef] [Green Version]
  78. Matthijs Blankesteijn, W. Has the search for a marker of activated fibroblasts finally come to an end? J. Mol. Cell. Cardiol. 2015, 88, 120–123. [Google Scholar] [CrossRef]
  79. Camelliti, P.; Borg, T.K.; Kohl, P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 2005, 65, 40–51. [Google Scholar] [CrossRef]
  80. Lane, E.B.; Hogan, B.L.; Kurkinen, M.; Garrels, J.I. Co-expression of vimentin and cytokeratins in parietal endoderm cells of early mouse embryo. Nature 1983, 303, 701–704. [Google Scholar] [CrossRef]
  81. Frangogiannis, N. Transforming growth factor-beta in tissue fibrosis. J. Exp. Med. 2020, 217, e20190103. [Google Scholar] [CrossRef]
  82. Meng, X.M.; Nikolic-Paterson, D.J.; Lan, H.Y. TGF-beta: The master regulator of fibrosis. Nat. Rev. Nephrol. 2016, 12, 325–338. [Google Scholar] [CrossRef]
  83. Biernacka, A.; Dobaczewski, M.; Frangogiannis, N.G. TGF-beta signaling in fibrosis. Growth Factors 2011, 29, 196–202. [Google Scholar] [CrossRef] [Green Version]
  84. Patel, N.J.; Nassal, D.M.; Greer-Short, A.D.; Unudurthi, S.D.; Scandling, B.W.; Gratz, D.; Xu, X.; Kalyanasundaram, A.; Fedorov, V.V.; Accornero, F.; et al. betaIV-Spectrin/STAT3 complex regulates fibroblast phenotype, fibrosis, and cardiac function. JCI Insight 2019, 4, e131046. [Google Scholar] [CrossRef]
  85. Dobaczewski, M.; Chen, W.; Frangogiannis, N.G. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J. Mol. Cell Cardiol. 2011, 51, 600–606. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  86. Schmierer, B.; Hill, C.S. TGFbeta-SMAD signal transduction: Molecular specificity and functional flexibility. Nat. Rev. Mol. Cell Biol. 2007, 8, 970–982. [Google Scholar] [CrossRef] [PubMed]
  87. Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425, 577–584. [Google Scholar] [CrossRef] [PubMed]
  88. Yamashita, M.; Fatyol, K.; Jin, C.; Wang, X.; Liu, Z.; Zhang, Y.E. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol. Cell 2008, 31, 918–924. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Lee, M.K.; Pardoux, C.; Hall, M.C.; Lee, P.S.; Warburton, D.; Qing, J.; Smith, S.M.; Derynck, R. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J. 2007, 26, 3957–3967. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  90. Bhowmick, N.A.; Ghiassi, M.; Bakin, A.; Aakre, M.; Lundquist, C.A.; Engel, M.E.; Arteaga, C.L.; Moses, H.L. Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol. Biol. Cell 2001, 12, 27–36. [Google Scholar] [CrossRef]
  91. Bakin, A.V.; Tomlinson, A.K.; Bhowmick, N.A.; Moses, H.L.; Arteaga, C.L. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 2000, 275, 36803–36810. [Google Scholar] [CrossRef] [Green Version]
  92. Yamaguchi, K.; Nagai, S.; Ninomiya-Tsuji, J.; Nishita, M.; Tamai, K.; Irie, K.; Ueno, N.; Nishida, E.; Shibuya, H.; Matsumoto, K. XIAP, a cellular member of the inhibitor of apoptosis protein family, links the receptors to TAB1-TAK1 in the BMP signaling pathway. EMBO J. 1999, 18, 179–187. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Woodgett, J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990, 9, 2431–2438. [Google Scholar] [CrossRef] [PubMed]
  94. Doble, B.W.; Woodgett, J.R. GSK-3: Tricks of the trade for a multi-tasking kinase. J. Cell Sci. 2003, 116, 1175–1186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  95. Frame, S.; Cohen, P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 2001, 359, 1–16. [Google Scholar] [CrossRef] [PubMed]
  96. Lal, H.; Ahmad, F.; Woodgett, J.; Force, T. The GSK-3 family as therapeutic target for myocardial diseases. Circ. Res. 2015, 116, 138–149. [Google Scholar] [CrossRef] [PubMed]
  97. Woulfe, K.C.; Gao, E.; Lal, H.; Harris, D.; Fan, Q.; Vagnozzi, R.; DeCaul, M.; Shang, X.; Patel, S.; Woodgett, J.R.; et al. Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo. Circ. Res. 2010, 106, 1635–1645. [Google Scholar] [CrossRef]
  98. Matsuda, T.; Zhai, P.; Maejima, Y.; Hong, C.; Gao, S.; Tian, B.; Goto, K.; Takagi, H.; Tamamori-Adachi, M.; Kitajima, S.; et al. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc. Natl. Acad. Sci. USA 2008, 105, 20900–20905. [Google Scholar] [CrossRef] [Green Version]
  99. Kerkela, R.; Kockeritz, L.; Macaulay, K.; Zhou, J.; Doble, B.W.; Beahm, C.; Greytak, S.; Woulfe, K.; Trivedi, C.M.; Woodgett, J.R.; et al. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J. Clin. Investig. 2008, 118, 3609–3618. [Google Scholar] [CrossRef] [Green Version]
  100. Michael, A.; Haq, S.; Chen, X.; Hsich, E.; Cui, L.; Walters, B.; Shao, Z.; Bhattacharya, K.; Kilter, H.; Huggins, G.; et al. Glycogen synthase kinase-3beta regulates growth, calcium homeostasis, and diastolic function in the heart. J. Biol. Chem. 2004, 279, 21383–21393. [Google Scholar] [CrossRef] [Green Version]
  101. Hardt, S.E.; Sadoshima, J. Glycogen synthase kinase-3beta: A novel regulator of cardiac hypertrophy and development. Circ. Res. 2002, 90, 1055–1063. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  102. Haq, S.; Choukroun, G.; Kang, Z.B.; Ranu, H.; Matsui, T.; Rosenzweig, A.; Molkentin, J.D.; Alessandrini, A.; Woodgett, J.; Hajjar, R.; et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 2000, 151, 117–130. [Google Scholar] [CrossRef]
  103. Guo, Y.; Gupte, M.; Umbarkar, P.; Singh, A.P.; Sui, J.Y.; Force, T.; Lal, H. Entanglement of GSK-3beta, beta-catenin and TGF-beta1 signaling network to regulate myocardial fibrosis. J. Mol. Cell. Cardiol. 2017, 110, 109–120. [Google Scholar] [CrossRef] [PubMed]
  104. Kim, W.; Kim, M.; Jho, E.H. Wnt/beta-catenin signalling: From plasma membrane to nucleus. Biochem. J. 2013, 450, 9–21. [Google Scholar] [CrossRef]
  105. Hernandez, G.; Lal, H.; Fidalgo, M.; Guerrero, A.; Zalvide, J.; Force, T.; Pombo, C.M. A novel cardioprotective p38-MAPK/mTOR pathway. Exp. Cell Res. 2011, 317, 2938–2949. [Google Scholar] [CrossRef] [Green Version]
  106. Cuadrado, A.; Nebreda, A.R. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 2010, 429, 403–417. [Google Scholar] [CrossRef] [Green Version]
  107. Lal, H.; Verma, S.K.; Golden, H.B.; Foster, D.M.; Smith, M.; Dostal, D.E. Stretch-induced regulation of angiotensinogen gene expression in cardiac myocytes and fibroblasts: Opposing roles of JNK1/2 and p38alpha MAP kinases. J. Mol. Cell. Cardiol. 2008, 45, 770–778. [Google Scholar] [CrossRef] [Green Version]
  108. Turner, N.A.; Blythe, N.M. Cardiac Fibroblast p38 MAPK: A Critical Regulator of Myocardial Remodeling. J. Cardiovasc. Dev. Dis. 2019, 6, 27. [Google Scholar] [CrossRef] [Green Version]
  109. Gurevich, V.V.; Gurevich, E.V. GPCR Signaling Regulation: The Role of GRKs and Arrestins. Front. Pharmacol. 2019, 10, 125. [Google Scholar] [CrossRef] [Green Version]
  110. Premont, R.T.; Gainetdinov, R.R. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu. Rev. Physiol. 2007, 69, 511–534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  111. Pitcher, J.A.; Freedman, N.J.; Lefkowitz, R.J. G protein-coupled receptor kinases. Annu. Rev. Biochem. 1998, 67, 653–692. [Google Scholar] [CrossRef] [Green Version]
  112. Pfleger, J.; Gresham, K.; Koch, W.J. G protein-coupled receptor kinases as therapeutic targets in the heart. Nat. Rev. Cardiol. 2019, 16, 612–622. [Google Scholar] [CrossRef]
  113. Belmonte, S.L.; Blaxall, B.C. G protein coupled receptor kinases as therapeutic targets in cardiovascular disease. Circ. Res. 2011, 109, 309–319. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Tanner, M.A.; Thomas, T.P.; Maitz, C.A.; Grisanti, L.A. beta2-Adrenergic Receptors Increase Cardiac Fibroblast Proliferation Through the Galphas/ERK1/2-Dependent Secretion of Interleukin-6. Int. J. Mol. Sci. 2020, 21, 8507. [Google Scholar] [CrossRef] [PubMed]
  115. Zheng, Y.; Pan, D. The Hippo Signaling Pathway in Development and Disease. Dev. Cell 2019, 50, 264–282. [Google Scholar] [CrossRef]
  116. Meng, Z.; Moroishi, T.; Guan, K.L. Mechanisms of Hippo pathway regulation. Genes. Dev. 2016, 30, 1–17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  117. Zhao, B.; Tumaneng, K.; Guan, K.L. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat. Cell Biol. 2011, 13, 877–883. [Google Scholar] [CrossRef]
  118. Sun, Y.; Yong, K.M.; Villa-Diaz, L.G.; Zhang, X.; Chen, W.; Philson, R.; Weng, S.; Xu, H.; Krebsbach, P.H.; Fu, J. Hippo/YAP-mediated rigidity-dependent motor neuron differentiation of human pluripotent stem cells. Nat. Mater. 2014, 13, 599–604. [Google Scholar] [CrossRef] [Green Version]
  119. Aragona, M.; Panciera, T.; Manfrin, A.; Giulitti, S.; Michielin, F.; Elvassore, N.; Dupont, S.; Piccolo, S. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors. Cell 2013, 154, 1047–1059. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  120. Wang, J.; Liu, S.; Heallen, T.; Martin, J.F. The Hippo pathway in the heart: Pivotal roles in development, disease, and regeneration. Nat. Rev. Cardiol. 2018, 15, 672–684. [Google Scholar] [CrossRef]
  121. Xiao, Y.; Hill, M.C.; Zhang, M.; Martin, T.J.; Morikawa, Y.; Wang, S.; Moise, A.R.; Wythe, J.D.; Martin, J.F. Hippo Signaling Plays an Essential Role in Cell State Transitions during Cardiac Fibroblast Development. Dev. Cell 2018, 45, 153–169. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  122. Umbarkar, P.; Singh, A.P.; Tousif, S.; Zhang, Q.; Sethu, P.; Lal, H. Repurposing Nintedanib for pathological cardiac remodeling and dysfunction. Pharmacol. Res. 2021, 169, 105605. [Google Scholar] [CrossRef] [PubMed]
Cells 10 02412 g001 550
Figure 1. Co-operation of canonical Wnt/β-Catenin and TGF-β1-SMAD3 signaling in fibrosis. In the canonical TGF-β1-SMAD3 pathway, the binding of ligands (TGF-β) to TGF-βR leads to the phosphorylation of R-SMADs (SMAD2 and SMAD-3). Phosphorylated R-SMADs promote the association with Co-SMAD (SMAD4), resulting in nuclear translocation to mediate the pro-fibrotic gene program. The sketch shows the critical crosstalk between the canonical TGF-β1 pathway and the Wnt/β-catenin signaling. Wnt/β-catenin signaling has a dual role in pro-fibrotic signaling: (I) the direct effect of nuclear β-catenin on pro-fibrotic gene program and (II) an indirect effect through the modulation of the TGF-β1 pathway. APC = Adenomatous Polyposis Coli; β-TrCP = β-transducin repeat-containing protein CK1; Col = Collagen; Dvl = Disheveled; FSP1 = Fibroblast-specific protein 1; GSK-3 = Glycogen synthase kinase 3; MMP = Matrix metalloproteinases; PAI-1 = Plasminogen activator inhibitor-1; Smad = Contraction of Sma and Mad (Mothers against decapentaplegic); TGF-β1 = Transforming growth factor beta 1; TIMP = Tissue inhibitors of MMPs.
Figure 1. Co-operation of canonical Wnt/β-Catenin and TGF-β1-SMAD3 signaling in fibrosis. In the canonical TGF-β1-SMAD3 pathway, the binding of ligands (TGF-β) to TGF-βR leads to the phosphorylation of R-SMADs (SMAD2 and SMAD-3). Phosphorylated R-SMADs promote the association with Co-SMAD (SMAD4), resulting in nuclear translocation to mediate the pro-fibrotic gene program. The sketch shows the critical crosstalk between the canonical TGF-β1 pathway and the Wnt/β-catenin signaling. Wnt/β-catenin signaling has a dual role in pro-fibrotic signaling: (I) the direct effect of nuclear β-catenin on pro-fibrotic gene program and (II) an indirect effect through the modulation of the TGF-β1 pathway. APC = Adenomatous Polyposis Coli; β-TrCP = β-transducin repeat-containing protein CK1; Col = Collagen; Dvl = Disheveled; FSP1 = Fibroblast-specific protein 1; GSK-3 = Glycogen synthase kinase 3; MMP = Matrix metalloproteinases; PAI-1 = Plasminogen activator inhibitor-1; Smad = Contraction of Sma and Mad (Mothers against decapentaplegic); TGF-β1 = Transforming growth factor beta 1; TIMP = Tissue inhibitors of MMPs.
Cells 10 02412 g001
Cells 10 02412 g002 550
Figure 2. Molecular mechanism of p38 MAPK-mediated pro-fibrotic signaling. The p38 pathway is a critical positive regulator of myocardial fibrosis. At the receptor level, p38 signaling is activated by a variety of stimuli, including Ang II (AT1R), mechanical sensing (integrins), and inflammatory cytokines (TGF-βR, TLR4). These membrane-proximal events lead to the activation of MKK3/6, the specific upstream activator of the p38 MAPK kinases. Once activated, p38 crosstalk with IKK-NFkB signaling and Hippo effector YAP to mediate the pro-fibrotic (Col-1, Col-3, FN, and α-SMA) and pro-inflammatory (Il-1b, IL-6, TNF-α) gene programs. Ang II = Angiotensin II; α-SMA = Alpha-smooth muscle actin; AT1R = Angiotensin II receptor; Col = Collagen; ECM = Extracellular Matrix; FAK = Focal adhesion kinase; GBR2 = Growth factor receptor-bound protein 2; IKK = IκB kinase; IL = Interleukin; ILK = Integrin-linked kinase; IRAK4 = Interleukin 1 receptor-associated kinase 1; MKK = Mitogen-activated protein kinase kinase; MyD88 = Myeloid differentiation factor 88; NFkB = Nuclear factor κ B; RhoA = Ras homolog family member A; Shc = SH2-containing collagen-related proteins; SOS complex = Son of sevenless guanine nucleotide exchange factor; SRF = Serum response factor; TAB1 = TAK binding protein 1; TAK1 = TGF-β-activated kinase 1; TEAD = TEA domain family member; TGF-β1 = Transforming growth factor beta 1; TGF-βR = TGF-β receptor; TLR4 = Toll-like receptor 4; TNF-α = TNF, tumor necrosis factor α; TRAF6 = TNF receptor-associated factor; YAP 1 = Yes-associated protein 1.
Figure 2. Molecular mechanism of p38 MAPK-mediated pro-fibrotic signaling. The p38 pathway is a critical positive regulator of myocardial fibrosis. At the receptor level, p38 signaling is activated by a variety of stimuli, including Ang II (AT1R), mechanical sensing (integrins), and inflammatory cytokines (TGF-βR, TLR4). These membrane-proximal events lead to the activation of MKK3/6, the specific upstream activator of the p38 MAPK kinases. Once activated, p38 crosstalk with IKK-NFkB signaling and Hippo effector YAP to mediate the pro-fibrotic (Col-1, Col-3, FN, and α-SMA) and pro-inflammatory (Il-1b, IL-6, TNF-α) gene programs. Ang II = Angiotensin II; α-SMA = Alpha-smooth muscle actin; AT1R = Angiotensin II receptor; Col = Collagen; ECM = Extracellular Matrix; FAK = Focal adhesion kinase; GBR2 = Growth factor receptor-bound protein 2; IKK = IκB kinase; IL = Interleukin; ILK = Integrin-linked kinase; IRAK4 = Interleukin 1 receptor-associated kinase 1; MKK = Mitogen-activated protein kinase kinase; MyD88 = Myeloid differentiation factor 88; NFkB = Nuclear factor κ B; RhoA = Ras homolog family member A; Shc = SH2-containing collagen-related proteins; SOS complex = Son of sevenless guanine nucleotide exchange factor; SRF = Serum response factor; TAB1 = TAK binding protein 1; TAK1 = TGF-β-activated kinase 1; TEAD = TEA domain family member; TGF-β1 = Transforming growth factor beta 1; TGF-βR = TGF-β receptor; TLR4 = Toll-like receptor 4; TNF-α = TNF, tumor necrosis factor α; TRAF6 = TNF receptor-associated factor; YAP 1 = Yes-associated protein 1.
Cells 10 02412 g002
Cells 10 02412 g003 550
Figure 3. GPCR-mediated myocardial pro-fibrotic signaling. The G-protein-coupled receptor kinases (GRKs) are crucial for GPCR signaling. GRKs are the critical positive regulator of fibroblast activation and myocardial fibrosis. GRKs mediate pro-fibrotic effects by modulating cAMP levels and NF-κB signaling. Furthermore, GRKs interact with NFAT to potentiate NFAT: DNA binding, thereby inducing the transcription of NFAT-mediated fibrotic genes. α-SMA = Alpha-smooth muscle actin; cAMP = Cyclic adenosine monophosphate; EPAC = Exchange protein activated by cAMP; GRK = G-protein-coupled receptor kinases; IkB = Inhibitor of NF-κB; NFAT = Nuclear factor of activated T-cells; NFκB = Nuclear factor-kappa B; PKA = Protein kinase A; TGF-β1 = Transforming growth factor beta 1; TNF = Tumor necrosis factor.
Figure 3. GPCR-mediated myocardial pro-fibrotic signaling. The G-protein-coupled receptor kinases (GRKs) are crucial for GPCR signaling. GRKs are the critical positive regulator of fibroblast activation and myocardial fibrosis. GRKs mediate pro-fibrotic effects by modulating cAMP levels and NF-κB signaling. Furthermore, GRKs interact with NFAT to potentiate NFAT: DNA binding, thereby inducing the transcription of NFAT-mediated fibrotic genes. α-SMA = Alpha-smooth muscle actin; cAMP = Cyclic adenosine monophosphate; EPAC = Exchange protein activated by cAMP; GRK = G-protein-coupled receptor kinases; IkB = Inhibitor of NF-κB; NFAT = Nuclear factor of activated T-cells; NFκB = Nuclear factor-kappa B; PKA = Protein kinase A; TGF-β1 = Transforming growth factor beta 1; TNF = Tumor necrosis factor.
Cells 10 02412 g003
Cells 10 02412 g004 550
Figure 4. Hippo pathway and myocardial fibrosis. When Hippo signaling is on (left), the mammalian STE20-like protein kinase 1 (MST1), MST2, and the Sav family WW domain-containing protein 1 (SAV1) complex activate the large tumour suppressor homologue 1 (LATS1) and LATS2 kinases, which in turn phosphorylate and promote the degradation of the downstream effectors YAP and TAZ. When Hippo signaling is off (right), YAP and TAZ function as transcriptional co-activators and partner with different transcription factors to regulate gene transcription. Active Hippo signaling is essential to maintain fibroblasts in their inactive state (calm). However, Hippo signaling is switched off in activated fibroblasts, leading to YAP/TAZ nuclear localization for the mediation of pro-fibrotic signaling (right). CTGF = Connective tissue growth factor; ECM = Extracellular matrix; FAK = Focal adhesion kinase; Gα and Gq = G protein subunit; ILK = Integrin-linked kinase; LATS 1/2 = Large Tumor Suppressor; MOB1 = Mps One Binder 1; MST 1/2 = Mammalian Ste20-like 1 and 2; PAI-1 = Plasminogen activator inhibitor-1Roa; Smad = Contraction of Sma and Mad (Mothers against decapentaplegic); TAZ = Transcriptional co-activator with PDZ-binding motif; YAP = Yes-associated protein.
Figure 4. Hippo pathway and myocardial fibrosis. When Hippo signaling is on (left), the mammalian STE20-like protein kinase 1 (MST1), MST2, and the Sav family WW domain-containing protein 1 (SAV1) complex activate the large tumour suppressor homologue 1 (LATS1) and LATS2 kinases, which in turn phosphorylate and promote the degradation of the downstream effectors YAP and TAZ. When Hippo signaling is off (right), YAP and TAZ function as transcriptional co-activators and partner with different transcription factors to regulate gene transcription. Active Hippo signaling is essential to maintain fibroblasts in their inactive state (calm). However, Hippo signaling is switched off in activated fibroblasts, leading to YAP/TAZ nuclear localization for the mediation of pro-fibrotic signaling (right). CTGF = Connective tissue growth factor; ECM = Extracellular matrix; FAK = Focal adhesion kinase; Gα and Gq = G protein subunit; ILK = Integrin-linked kinase; LATS 1/2 = Large Tumor Suppressor; MOB1 = Mps One Binder 1; MST 1/2 = Mammalian Ste20-like 1 and 2; PAI-1 = Plasminogen activator inhibitor-1Roa; Smad = Contraction of Sma and Mad (Mothers against decapentaplegic); TAZ = Transcriptional co-activator with PDZ-binding motif; YAP = Yes-associated protein.
Cells 10 02412 g004
Table
Table 1. List of proteins/markers that have been targeted in order to create mouse lines for FB-specific genetic manipulation and lineage tracing.
Table 1. List of proteins/markers that have been targeted in order to create mouse lines for FB-specific genetic manipulation and lineage tracing.
Proteins/MarkersBiological RoleExpression in FB StatesExpression in Other CellsReferences
PeriostinECM proteinDevelopmental stage, activated FBsEpicardium[9,18,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44]
TCF21Transcription factorResting FB, downregulate in activated FBsEpicardium[9,20,22,23,31,37,41,43,44,45,46,47,48,49]
α-SMACytoskeletal proteinActivated FBsPericytes, VSMC, Epicardium[6,9,12,25,50]
Collagen I, IIIECM proteinResting and activated FBsPericytes, VSMC, Endothelial cells, Cardiomyocytes[12,20,22,25,26,27,45,51,52,53,54,55,56,57,58,59,60,61,62]
CD90Cell-cell interactionResting and activated FBsPericytes, VSMC, immune cells, Endothelial cells[12,27,45,51,52,53]
DDR2Cell-ECM interactionResting FBsEpicardium[22,25,63,64,65]
FSP1Calcium binding proteinResting and activated FBsPericytes, VSMC, Immune cells, Endothelial cells[9,18,19,22,23,25,66,67]
FibronectinECM proteinResting and activated FBsEndothelial cells[22,68,69,70]
PDGFRαTyrosine kinase receptorResting and activated FBsCardiac progenitor cells[9,12,22,25,71,72,73]
Stem cells antigen-1Stem cell antigenResting and activated FBsCardiac progenitor cells[22,74,75,76]
VimentinCytoskeletal proteinResting and activated FBsPericytes, VSMC, Endothelial cells[22,25,77,78,79,80]
Table
Table 2. Studies carried out with FB-specific, genetically manipulated mouse models.
Table 2. Studies carried out with FB-specific, genetically manipulated mouse models.
Target GenePromoter Used for Cre ExpressionMajor FindingsReferences
Tgfbr1/2, Smad2, Smad3PostnFB-specific deletion of Tgfbr1/2 or Smad3, but not Smad2, markedly reduced fibrosis in pressure-overloaded mouse hearts as well as fibrosis mediated by heart-specific, latency-resistant TGF-β mutant transgene.[33]
Smad3PostnIn pressure-overloaded hearts, the protective actions of the myofibroblasts were mediated through Smad3-dependent matrix-preserving program[38]
Smad3PostnFB-specific Smad3 loss impaired scar remodeling and increased the incidence of late rupture post-MI[35]
Tgfbr2PostnTgfbr2 ablation in the myofibroblast prevented fibrosis and cardiac dysfunction in mouse model of cMyBP-C-induced cardiomyopathy[36]
Gsk3bPostnFB-specific deletion of GSK-3β lead to the hyperactivation of SMAD-3, resulting in excessive fibrotic remodeling and cardiac dysfunction after myocardial infarction.[26]
Gsk3aTcf21 and PostnIn pressure-overloaded hearts, FB-specific GSK-3α mediated pro-fibrotic effects through an ERK-IL-11 circuit that operated independently of TGF-β/SMAD3 signaling[44]
Ctnb1Tcf21 and PostnLoss of β-catenin in fibroblasts attenuated pressure-overload-induced cardiac fibrosis[43]
p38Tcf21 and PostnFB-specific deletion of p38 attenuated myofibroblasts transformation and fibrosis. Conversely, transgenic mice expressing constitutively active p38 in FB specific manner develops fibrosis in multiple organs.[37]
p38PostnSpatial variations in collagen organization regulated cardiac fibroblast phenotype through the mechanical activation of p38-YAP-TEAD signaling[30]
Grk2PostnAblation of GRK2 in activated fibroblasts significantly reduced myofibroblast transformation and fibrosis and showed cardiovascular protection post-I/R injury[42]
Lats1/2Tcf21FB-specific deletion of Lats1 and Lats2 initiated a self-perpetuating fibrotic response in the uninjured adult heart that was exacerbated by MI[47]
YapTcf21FB-specific deletion of YAP prevented MI-induced cardiac fibrosis and dysfunction through MRTF-A inhibition.[46]
Htr2bTcf21 and PostnDeletion of 5-HT2B receptor signaling in fibroblast prevented border zone expansion and improved microstructural remodeling after MI[41]
Hsp47PostnMyofibroblast-specific ablation of Hsp47 blocked fibrosis in mouse models of pressure overload, MI and, muscular dystrophy[34]
Sox9PostnFB-specific deletion of Sox9 ameliorated MI-induced left ventricular dysfunction, inflammation, and myocardial scarring[39]
Kcnk2Tcf21FB-specific deletion of TREK1 prevented pressure-overload-induced deterioration in cardiac function[48]
Rock2PostnDeletion of ROCK2 in fibroblast attenuated cardiac hypertrophy, fibrosis, and diastolic dysfunction in mice subjected to chronic Ang-II infusion[40]
Fn1Tcf21FB-specific fibronectin gene ablation ameliorated adverse cardiac remodeling and fibrosis post I/R[49]
Prkaa1PostnAMPKα1 deletion in myofibroblasts exacerbated post-MI adverse fibrotic remodeling[32]
Sptbn4PostnFB-specific deletion of βIV-spectrin aggravated Ang-II induced fibrosis and cardiac dysfunction.[84]
Pmca4PostnFB-deletion of PMCA4 reduced TAC-induced hypertrophy and cardiac dysfunction[24]
Mbnl1Tcf21 and PostnDeletion of MBNL1 impaired the fibrotic phase of wound healing in mouse models of MI.[31]
Klf5PostnFB–specific KLF5 deletion ameliorated TAC-induced cardiac hypertrophy and fibrosis[27]
PostnTcf21 and PostnAblation periostin expressing FBs reduced collagen production and scar formation after MI.[9]
PostnPostnAblation of periostin expressing FBs reduced fibrosis and improved cardiac function in mice subjected to chronic Ang-II infusion as well as in mice after MI[21]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Umbarkar, P.; Ejantkar, S.; Tousif, S.; Lal, H. Mechanisms of Fibroblast Activation and Myocardial Fibrosis: Lessons Learned from FB-Specific Conditional Mouse Models. Cells 2021, 10, 2412. https://doi.org/10.3390/cells10092412

AMA Style

Umbarkar P, Ejantkar S, Tousif S, Lal H. Mechanisms of Fibroblast Activation and Myocardial Fibrosis: Lessons Learned from FB-Specific Conditional Mouse Models. Cells. 2021; 10(9):2412. https://doi.org/10.3390/cells10092412

Chicago/Turabian Style

Umbarkar, Prachi, Suma Ejantkar, Sultan Tousif, and Hind Lal. 2021. "Mechanisms of Fibroblast Activation and Myocardial Fibrosis: Lessons Learned from FB-Specific Conditional Mouse Models" Cells 10, no. 9: 2412. https://doi.org/10.3390/cells10092412

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop